RE:RE:RE:RE:I have concluded that...Thank you for the reach out. Here is my thoughts on the most recent share price movement.
Firstly, it is not a takeover so no poison pill needs discussion. Why? Medx is only a 40 million market cap company and just starting its revenue ramp.In a year or two once MedX has a global footprint and stable growing revenue derived from it's SaaS model then a strategic player would make sense. The recent volume doesn't even reach 2% of the float and it is comming from multiple houses so I do not think a takeover is in the works.
MedX has been a turnaround the new management team has been painful with its news as it was building a platform and the management tends to only put out news when it is material in nature. (This has been really frustrating) This has changed. They have finally hired two professional IR teams that have been starting to get more eyes on the company. MedX had a very small interested base of shareholders. The older shareholders have been selling their shares for the last few years as their patients wore out waiting and their were other hot stocks they could play.
Share price movement recently???
Shareholders were worried that MedX was out of money and would not be able to raise anymore capital now that they are funded I think that signals two things a) they have a strong balance sheet b) they must have a strong story as the institutional money stepped in again to finance them.
MedX has hire two professional IR firms and they have been getting fresh eyes on the story.
More importantly MedX has finally gone from the "proof of concept" stage to full commercialization. Most shareholders missed the significance of this press release in December;
https://stockhouse.com/news/press-releases/2020/12/14/medx-health-corp-announces-the-rollout-of-dermsecure-xae-in-the-netherlands
This is significant because the numbersshow this has the potential to produce between $1.5 million to $2.5 million a year of recurring revenue and that is 1 small country installation. It is up and running and I expect it to really show in Q3-Q4
If you compare it to any other speciaty telemedicine compinies it it decidedly undervalued. So I expect much more news coming or MedX wouldn't have wasted the money on IR and I think with fresh investor eyes on board and some solid contracts shareholders will be suprised at how undervalued MedX truly is.
I hope this is what you were asking for.